Cited by 151Advanced Glycation End Products researchDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death

Open access
Selvin, Elizabeth, Rawlings, Andreea M., Lutsey, Pamela L., Maruthur, Nisa, Pankow, James S., Steffes, Michael, Coresh, Josef·2015·Circulation

Abstract

Background—: Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. Methods and Results—: We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and—as has been previously observed for HbA1c—the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker. Conclusions—: The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.115.015415

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nontraditional glycemic targets, such as fructosamine and glycated albumin, have been associated with CV outcomes and mortality in a cohort study, but their broader utility and correlation with A1C have not yet been established.

    “Although, nontraditional glycemic targets, such as fructosamine and glycated albumin, have also been associated with CV outcomes and mortality in a cohort study (51), the broader utility of such targets and their correlation with A1C has not yet been established.”

    From Targets for Glycemic Control (2018) · cites this paper as [51]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [5]Type 2 diabetes: national clinical guideline for management in primary and secondary care (update) 2008 21678628

Cited by

Sorted by citations

Authors
Selvin, E., Rawlings, A. M., Lutsey, P. L., Maruthur, N., Pankow, J. S., Steffes, M., & Coresh, J.
Affiliations
University of Minnesota (US)
Venue
Circulation
Published
2015-07-28
Volume
132
Issue
4
Pages
269-277
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2141579512
Cited by
151
References
39
Citations by year
2026: 8 · 2025: 10 · 2024: 20 · 2023: 12 · 2022: 17 · 2021: 19 · 2020: 14 · 2019: 13 · 2018: 13 · 2017: 16 · 2016: 8 · 2015: 1
FWCI
10.47
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Asahi Kasei Pharma Corporation
  • National Institutes of Health (HHSN268201100012C, HHSN268201100008C, HHSN268201100006C, HHSN26820- 1100005C, HHSN268201100007C, HHSN268201100011C, HHSN268201100010C, UL1TR001079, HHSN268201100009C)
  • U.S. Public Health Service (HHSN268201100012C), HHSN2682 01100010C, HHSN268201100007 C, HHSN2682011-00008C, HHSN268201100 006C, HHSN2682‐01100011C, HHSN268201100009C, HHSN 268201100005C)
  • National Heart, Lung, and Blood Institute (HHSN268201 100012C, HHSN268201100007I, HHSN268201100007C, HHSN2682 01100008C, HH-SN-268201100006C, HHSN268201100011C, HHSN2682011-00005I, HHSN2682011-­00009I, HHSN268201100005C, HHSN268201100005G, HHSN268201100010C, HHSN268201100011I, HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C, HHSN26820 1100009C, HHSN2682011-00008I, T32HL007024, U01HL096812)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK089174, R01DK089174)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
fructosamine, glycated albumin, glycemic control, HbA1c, diabetes mellitus, cardiovascular risk, coronary artery disease, ischemic stroke, heart failure, mortality, Atherosclerosis Risk in Communities Study
MeSH terms
Glycated Serum Albumin, Coronary Disease, Female, Heart Failure, Glycated Hemoglobin, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Serum Albumin, Biomarkers, Survival Rate, Glycation End Products, Advanced, Fructosamine, Stroke, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review